Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Roivant Sciences

Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.

Investors Business Daily

Quick Facts About Vivek Ramaswamy: Net Worth, How He Met His Wife, Ohio Governor Run, and More

Vivek Ramaswamy, a biotech entrepreneur and former Republican presidential candidate, has announced his bid for Ohio governor as he secures Donald Trump's endorsement.

International Business Times UK

Roivant Sciences Gets Relative Strength Rating Upgrade

A Relative Strength Rating upgrade for Roivant Sciences shows improving technical performance. Will it continue?

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Roivant Sciences Earns Relative Strength Rating Upgrade

A Relative Strength Rating upgrade for Roivant Sciences shows improving technical performance. Will it continue?

Investors Business Daily

IBD Rating Upgrades: Roivant Sciences Flashes Improved Technical Strength

Roivant Sciences shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers

A Relative Strength Rating upgrade for Roivant stock shows improving technical performance. Will it continue?

Investors Business Daily

The 'Extremely Positive' Results That Helped Roivant Leapfrog Its 50-Day Line, Nearing A Breakout

Roivant stock is nearing a breakout Tuesday after the company announced positive results in an eye-disease study and a $1.5 billion buyback.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Is Roivant Sciences (ROIV) the Right Biotech Stock for Your Portfolio?

While Roivant Sciences (ROIV) has been seeing stable revenue growth, its bottom line is in the red. So, will it be worth owning ROIV now? Let’s discuss some of its key financial metrics to gauge its prospects.

StockNews.com

Vivek Ramaswamy: the ‘millennial tech bro’ running for president

The multimillionaire former biotech executive Vivek Ramaswamy took centre stage at the first Republican debate last week as he bids to win his party’s 2024 presidential nomination.

The Week

Who is Vivek Ramaswamy? Trump nominates Ramaswamy and Elon Musk to lead new efficiency department

Vivek Ramaswamy is the son of an immigrant family from Kerala

Evening Standard

11 Revived Stocks That Traded For $5 Or Less Are Now Worth Billions

Investors are even willing to dip into the cheap-stock territory outside the S&P 500 — and it's paying off handsomely so far.

Investors Business Daily

Analyst Ratings for Roivant Sciences

Within the last quarter, Roivant Sciences (NASDAQ:ROIV) has observed the following analyst ratings:

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 29, 2022

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.